Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats

The Sodium Glucose Co-Transporter-2 inhibitor, empagliflozin (EMPA), reduces mortality and hospitalisation for heart failure following myocardial infarction irrespective of diabetes status. While the findings suggest an inherent cardioprotective capacity, the mechanism remains unknown. We studied in...

Descripción completa

Detalles Bibliográficos
Autores principales: Seefeldt, Jacob Marthinsen, Lassen, Thomas Ravn, Hjortbak, Marie Vognstoft, Jespersen, Nichlas Riise, Kvist, Frederikke, Hansen, Jakob, Bøtker, Hans Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100147/
https://www.ncbi.nlm.nih.gov/pubmed/33953281
http://dx.doi.org/10.1038/s41598-021-89149-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100147/
https://www.ncbi.nlm.nih.gov/pubmed/33953281
http://dx.doi.org/10.1038/s41598-021-89149-9

Ejemplares similares